US MSO (Management Services Organization) Structure and Marketing · 2026 Playbook

1. The MSO structure in plain language

Start with the constraint. Roughly 30 US states restrict who can own a medical or dental practice — those restrictions are collectively known as corporate-practice-of-medicine (CPM) rules and they exist to preserve clinical decision-making inside a licensed clinician's judgment rather than a corporate boardroom. The rules pre-date the modern investor era; they were written in the 1930s and 1950s in most states to prevent lay-owned corporations from directing physician care.

Modern healthcare capital — private equity, hospital systems, publicly traded operators, insurers with delivery arms — needs a way to participate in the economics of clinical practice without violating those rules. The Management Services Organization structure is that way. The professional corporation (PC) is owned entirely by one or more licensed clinicians and holds the clinical practice — the malpractice policy, the patient records, the professional employment contracts, the licensure. The MSO is a separate non-clinical corporate entity, owned by the capital sponsor, that provides operational services to the PC under an administrative-services agreement (ASA). The ASA specifies which services the MSO provides (real estate, IT, HR, billing, marketing, purchasing, revenue cycle) and what the PC pays the MSO for those services.

Structurally: patients see the PC. The PC bills insurance. Insurance reimburses the PC. The PC pays the MSO an administrative-services fee out of collections. The MSO uses that fee to cover the operating cost and return capital to the sponsor. The clinician remains the record owner of the practice and the licensed authority for clinical decisions. The MSO is invisible to the patient and, when done properly, invisible to the state medical board except during an audit.

2. Corporate-practice-of-medicine states — the enforcement map

The 30-odd states that enforce CPM rules vary meaningfully in enforcement rigour, and marketing partners working with multi-state platforms have to know the map. Strong-CPM states include California, Texas, New York, Illinois, New Jersey, Colorado, Ohio, Iowa, Washington and several others. California is the strictest, with active enforcement by the Medical Board of California and case law defining what constitutes lay control of a medical practice. Texas has its own peculiarities — hospitals cannot directly employ physicians in most cases, which shapes both hospital-system and PE structure design.

Weaker-CPM or effectively no-CPM states include Florida, Arizona, Georgia, Kansas and several others. These states either lack statutory CPM restrictions or enforce them so lightly that the MSO-plus-PC structure is unnecessary — an investor can directly own the medical practice as a business entity. Even in weak-CPM states, many PE-backed platforms adopt the MSO structure preemptively to simplify multi-state expansion and to protect the option value of entering strong-CPM states later.

3. What marketing the MSO owns versus what the PC owns

The single most useful rule for a marketing partner working inside an MSO-PC structure is this: the MSO owns the operations of marketing; the PC owns the clinical content of marketing. Operational marketing includes agency selection, media buying, creative production, brand governance, analytics platforms, martech stack, campaign execution, and reporting. Clinical marketing includes any claim that constitutes a clinical judgment — that a specific treatment is safe, that a specific outcome is achievable, that a specific clinician is expert at a specific procedure, that a specific patient benefited from a specific intervention.

Two practical examples. A campaign claim like "Book online, extended hours, financing available, insurance accepted" is operational — the MSO can create, approve and publish it without PC sign-off. A campaign claim like "Our dermatologists achieve superior biologics outcomes for moderate-to-severe psoriasis" is clinical — the PC must approve it, a named licensed clinician usually stands behind it, and in some states it must be attributed to a specific clinician by name.

The practical implication for a marketing partner is that the approval workflow for anything with a clinical claim runs through the PC and adds a real cycle time. Well-run platforms build a clinician-review-board that reviews clinical marketing claims on a weekly cadence; poorly-run platforms let clinical claims slip through the MSO's operational approval and create board-inquiry exposure at audit.

4. Payer contracting and MSO layer implications

Payer contracts (Medicare, Medicaid, commercial carriers) are held by the PC because the PC is the licensed clinical entity providing the service. The MSO cannot hold a payer contract for medical services in most states. The MSO can and often does hold contracts for non-clinical services (facility fees where structure permits, ancillary services, retail products) but the clinical fee-for-service arrangement stays inside the PC.

The marketing implication is around network-directory listings and in-network claim messaging. The PC is the entity listed in the payer directory; the marketing has to reflect that even when the PC brand is invisible in patient-facing communications. Some platforms deliberately dual-brand — the PC name shows up in payer directories and legal disclosures, the MSO-sponsored consumer brand shows up in patient-facing marketing — and the reconciliation between the two is a real content-management problem the marketing partner has to solve at the CMS layer of the website.

5. Brand-central versus per-clinician marketing

Physician specialties (derm, plastic, fertility, psychiatry) run a harder version of the brand-central versus per-clinician tension we described in the DSO and PE-portfolio playbooks. The consumer brand is often MSO-sponsored — it may be entirely a marketing construct created by the MSO — while the actual patient-trust vehicle is the individual clinician who provides the care. Well-run MSO structures publish clinician-authored content under the consumer brand umbrella; each clinician gets a bylined author page, a credentialed authority profile, a per-clinician content feed, and Person-schema markup that surfaces the clinician as the trust vehicle even when the consumer brand carries the reach.

Poorly-run MSO structures suppress the clinician brand entirely and lose both the trust conversion and the AI-Overview citation opportunity, which increasingly reads clinician-authorship signals as a proxy for E-E-A-T. Marketing partners should push the platform to invest in per-clinician content and profile pages even when the consumer brand is the dominant marketing vehicle.

6. Stakeholder map — MSO CEO, PC medical director, marketing lead

An MSO-PC structure has three marketing stakeholders. The MSO CEO (or COO) owns the operating outcome — patient volume, per-office contribution, marketing spend efficiency. The PC medical director (or CMO of the clinical entity) owns clinical content sign-off, clinician engagement in marketing, and any board-facing clinical claim. The marketing lead (may sit inside the MSO as VP Marketing or CMO) runs day-to-day marketing delivery and reports operationally to the MSO CEO while functionally routing clinical claims through the PC medical director.

A marketing partner has to earn the trust of all three. The MSO CEO's KPI is operational; the PC medical director's KPI is clinical defensibility; the marketing lead's KPI is delivery. Weekly per-office reporting satisfies the MSO CEO. Structured clinical-claim review satisfies the PC medical director. Systemised creative delivery satisfies the marketing lead. Do all three or expect stakeholder drift.

7. Compliance risks unique to MSO marketing

Two compliance risks matter disproportionately for MSO marketing structures and are worth naming explicitly because most agencies do not underwrite them.

Fee-splitting

Almost every state prohibits splitting professional fees between a licensed clinician and a non-licensed person or entity. The prohibition extends to MSO administrative-services agreements and to agency-compensation arrangements. If the MSO's fee to the PC is calculated as a percentage of the PC's clinical revenue, state regulators may treat the ASA as fee-splitting even when the parties label it otherwise. If an agency's fee is tied to a percentage of the new-patient revenue generated, the same recharacterisation risk applies. The safe-harbour structure is a fair-market-value flat fee for defined services, benchmarked against comparable market-rate services, documented in the ASA and refreshed periodically.

Anti-Kickback Statute (AKS) exposure

The federal Anti-Kickback Statute prohibits any remuneration in exchange for referring or arranging for the referral of a Medicare or Medicaid patient. Pay-per-lead compensation for federally-insured patients is high risk under AKS. Marketing engagements that generate leads for a Medicare-heavy practice (cardiology, cataract, joint replacement) need to be structured on flat-fee or hourly economics rather than lead-share or revenue-share economics. State kickback statutes layer on top for commercial patients in many states.

8. Ichelon Consulting US\'s MSO delivery model

Ichelon Consulting US (Dallas, TX) delivers into MSO-PC structures across derm, ophthal, ortho, GI and fertility platforms. Our delivery contract is structured as flat-fee retainer for defined services (brand, paid media, per-office GBP, per-office reporting) with defined scope adjustments quarterly, priced against fair market value benchmarks. We do not accept pay-per-lead economics on federally-insured patient populations. Every clinical marketing claim routes through the PC medical director for sign-off before publication.

Our engagement onboarding includes a compliance stack-check — confirmation of ASA structure with the client\'s general counsel, review of the payer mix (Medicare / Medicaid / commercial / self-pay), and design of the claim-approval workflow. First month deliverable includes a clean per-office contribution report the MSO CEO can read alongside a clinical-claim inventory the PC medical director can audit. Book a benchmarking call from the office card below.

Frequently asked